Regeneron Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Regeneron Pharmaceuticals, Inc. en bref

Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at 531,72 € with a market capitalization of 55,7 Md €. The trailing P/E ratio stands at 14.9x, with a forward P/E of 11.34x. The 52-week range spans from 441,44 € to 715,81 €; the current price is 25.7% below the yearly high. Year-over-year revenue growth stands at +19.0%. The net profit margin stands at 29.65%.

💰 Dividende

Regeneron Pharmaceuticals, Inc. pays an annual dividend of 3,28 € per share, representing a yield of 0.62%. The payout ratio stands at 8.74%.

📊 Avis des analystes

28 analystes évaluent Regeneron Pharmaceuticals, Inc. (REGN) au consensus : Acheter. L'objectif de cours moyen est de 726,45 €, soit un potentiel de +36.62% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 558,80 € à 871,76 €.

Regeneron Pharmaceuticals, Inc. : la thèse d'investissement en détail

Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 19% pace year-over-year, suggesting the business model continues to find new customers and pricing power. The combination of a 43.89% gross margin and 20.66% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 29.65%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valorisation en contexte

The PEG ratio at 1.07 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 11.34x is meaningfully below the trailing 14.9x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 36.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Regeneron Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.